Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Shaoxing Zhu"'
Autor:
Hailong Hu, Jianming Guo, Dahong Zhang, Jian Huang, Lilin Zhang, Ji-Yan Liu, Qing Zou, Aiping Zhou, Xiusong Qiu, Hanzhong Li, Dingwei Ye, Se Hoon Park, Yuanyuan Bao, Jie Jin, Lulin Ma, Cheng Fu, Shaoxing Zhu, F. Bi, Wei Shen, Jun Xiao
Publikováno v:
Cancer Science
Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistanc
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
ObjectivesTo evaluate the nature, diagnosis, treatment and prognosis of second primary renal cell carcinoma (SPRCC).Materials and MethodsWe retrospectively collected data from 118 patients with SPRCC. Clinical characteristics, imaging features and tr
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
Frontiers in Oncology
Frontiers in Oncology
IntroductionIn addition to being rare, metastases to the kidney present clinicians with issues regarding their treatment.Materials and MethodsWe retrospectively analyzed 35 cases of diagnosed renal metastases. The clinical characteristics, imaging fe
Publikováno v:
Journal of Clinical Oncology. 38:TPS588-TPS588
TPS588 Background: Platinum-based chemotherapy is standard first-line treatment for patients with advanced urothelial carcinoma (UC). Checkpoint inhibitors (ie, anti-PD-1 antibodies) are first-line treatment options for cisplatin-ineligible patients.
Autor:
Guiping Chen, Bo O. Chen, Hua Wang, Yipeng Xu, Yang Zhao, Shaoxing Zhu, Fangyin Li, Zongping Wang
Publikováno v:
Oncology Letters
Penile verrucous carcinoma is an extremely rare disease that, at present, has not been well characterized. The etiology, diagnosis and treatment of this carcinoma remain poorly understood, particularly in the Chinese population. The aim of the presen